Anti-HSP90 alpha Antibody, clone 4M13 ZooMAb^® Rabbit Monoclonal

200

rabbit (recombinant)

expressed in HEK 293 cells

unconjugated

purified antibody

primary antibodies

4M13, monoclonal
recombinant monoclonal

ZooMAb^® learn more

lyophilized

calculated mol wt 84.66 kDa
observed mol wt ~85 kDa

mouse, human

antibody small pack of 25 μL

Waste Prevention
Designing Safer Chemicals
Design for Energy Efficiency
Learn more about the Principles of Green Chemistry.

recombinant expression
Learn more about Antibody Enhanced Validation

affinity binding assay: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable

IgG

Aligned

ambient

2-8℃

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.

Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.

Learn more about ZooMAb here.

Clone 4M13 is a ZooMAb rabbit recombinant monoclonal antibody that specifically detects HSP90 alpha. It targets an epitope within the N-terminal half.

His-tagged recombinant fragment corresponding to 115 amino acids from the N-terminal half of human Heat shock protein HSP90 alpha.

Anti-HSP90 alpha, clone 4M13 ZooMAb, Cat. No. ZRB1502, is a recombinant Rabbit monoclonal antibody that specifically targets HSP90 alpha and is tested for use in Affinity Binding Assay, Immunohistochemistry (Paraffin), and Western Blotting.
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected HSP90 alpha in lysates from NIH3T3 cells, human testis, and rat brain tissue.

Affinity Binding Assay: A representative lot of this antibody bound human recombinant HSP90 alpha with a KD of 2.9 x 10-8 in an affinity binding assay.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected HSP90 alpha in human testis tissue sections.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 μL.

0.03 mg/mL after reconstitution at 25 μL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Heat shock protein HSP 90-alpha (UniProt: P07900; also known as Heat shock 86 kDa, HSP 86, HSP86, Lipopolysaccharide-associated protein 2, LAP-2, LPS-associated protein 2, Renal carcinoma antigen NY-REN-38) is encoded by the HSP90AA1 (also known as HSP90A, HSPC1, HSPCA) gene (Gene ID: 3320) in human. HSP90 serves as a molecular chaperone that maintains the stability and functionality of numerous client proteins in an ATPase-dependent manner. It is known to interact dynamically with various co-chaperones that modulate its substrate recognition, ATPase cycle, and chaperone function. After the completion of the chaperoning process, properly folded client protein and co-chaperone leave HSP90 in an ADP-bound partially open conformation and finally, ADP is released from HSP90 which acquires an open conformation for the next cycle. HSP90 and its co-chaperones are also shown to modulate transcription at least at three different levels (a) by altering the steady-state levels of certain transcription factors in response to various physiological cues (b) modulating the activity of certain epigenetic modifiers, such as histone deacetylases, and (c) by participation in the eviction of histones from the promoter region of certain genes and thereby turn on gene expression. In its resting state, through the dimerization of its C-terminal domain, HSP90 forms a homodimer, which is defined as the open conformation. Upon ATP-binding, the N-terminal domain undergoes significant conformational changes and comes in contact to form an active closed conformation. Following the completion of its chaperoning activity, ATP molecule is hydrolyzed to ADP which then dissociates from HSP90 and directs the protein back to the resting state. This monoclonal antibody (clone 1G6-D7) is reported to inhibit both de novo tumor formation and expansion of already formed tumors in mice. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Li, W., et al. (2012). Biochim. Biophys. Acta. 1823(3); 730 741; Zou, M., et al. (2017). Oncogene 36(15); 2160-2171).

Recommend storage of lyophilized product at 2-8℃; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 μL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8℃, or -20℃ for long term storage. Avoid repeated freeze-thaws.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

11 - Combustible Solids

WGK 1